Source comparison
MK-677 Versus Nutrobal: Why Different Names Exist
The proliferation of brand names for ibutamoren reflects the compound's unusual regulatory status. MK-677 was developed by Merck & Co. in the 1990s as a potential oral treatment for growth hormone deficiency and sarcopenia. Despite promising Phase II data, Mer
This comparison does not assign a generated winner or score.
- The proliferation of brand names for ibutamoren reflects the compound's unusual regulatory status. MK-677 was developed by Merck & Co. in the 1990s as a potential oral treatment for growth hormone deficiency and sarcopenia. Despite promising Phase II data, Merck discontinued development before Phase III trials. The compound never received FDA approval as a drug product. This left ibutamoren in regulatory limbo: proven in human trials but not approved for medical use, making it unavailable through prescription channels but accessible through research chemical suppliers operating under different regulatory frameworks.
- Research suppliers typically use 'MK-677' to reference the Merck developmental designation, signaling continuity with published clinical literature. Bodybuilding and nootropic vendors often market the same compound as 'Nutrobal'. A brand name with no pharmaceutical lineage but broader recognition in performance enhancement communities. Some suppliers use 'ibutamoren' directly, emphasizing the INN (International Nonproprietary Name) to signal pharmaceutical-grade sourcing. All three names describe the same molecule when the supplier provides third-party purity testing via HPLC-MS (high-performance liquid chromatography-mass spectrometry) showing ≥98% ibutamoren mesylate content.
- The risk isn't that Nutrobal and MK-677 are different compounds. It's that neither name guarantees purity or identity without verification. Underground labs and unregulated suppliers can label anything 'Nutrobal' or 'MK-677' without consequence. MK 677 sourced from verified suppliers includes certificate of analysis documentation showing exact purity, residual solvent levels, and heavy metal content. Essentials for research-grade material that casual vendors often omit.
- Chemical Identity
- Ibutamoren mesylate (CAS 159752-10-0) verified via NMR
- Claimed ibutamoren. No verification
- Third-party HPLC-MS confirmed ≥98% purity
- Only research-grade products with CoA documentation guarantee compound identity
- Dosing Precision
- Pharmaceutical-grade powder, exact mg/dose
- Variable purity, unknown active content per capsule
- Lyophilized powder or solution at stated concentration
- Dosing accuracy depends entirely on verified purity. Underground products often contain 40–70% stated dose
- Regulatory Oversight
- FDA-regulated clinical trial material (IND)
- No regulatory oversight, state-by-state legal variability
- FDA-registered 503B facility or international supplier under GMP
- Regulatory status varies: clinical trial material is most controlled, research-grade follows GMP, underground has zero oversight
- Typical Cost
- Not commercially available
- $30–$60 per month (claimed 25mg/day)
- $80–$120 per month (verified 25mg/day)
- Price reflects testing and compliance costs. Unusually cheap ibutamoren signals absent quality control
- Appetite Effect Onset
- 30–60 minutes post-dose across all trials
- User reports vary (inconsistent with ghrelin receptor pharmacology)
- Consistent 30–60 min onset matching clinical data
- If a product labeled MK-677 doesn't produce appetite stimulation within 1 hour, it likely contains minimal active compound